These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 20489417)

  • 1. Glucose lowering and cardiovascular disease: what do we know and what should we do?
    Cheng AY; Leiter LA
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S25-31. PubMed ID: 20489417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.
    Meier M; Hummel M
    Vasc Health Risk Manag; 2009; 5():859-71. PubMed ID: 19898642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Glycemic control and cardiovascular benefit: What do we know today?].
    Hanefeld M; Schönauer M; Forst T
    Dtsch Med Wochenschr; 2010 Feb; 135(7):301-7. PubMed ID: 20146161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive glycemic control and cardiovascular disease: an update.
    Brown A; Reynolds LR; Bruemmer D
    Nat Rev Cardiol; 2010 Jul; 7(7):369-75. PubMed ID: 20404853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hypoglycemia and cardiovascular risk].
    Avogaro A
    G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):4S-12S. PubMed ID: 25623545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes and cardiovascular disease: the role of glycemic control.
    Cheng AY; Leiter LA
    Curr Diab Rep; 2009 Feb; 9(1):65-72. PubMed ID: 19192427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycaemic control and macrovascular and microvascular outcomes: A systematic review and meta-analysis of trials investigating intensive glucose-lowering strategies in people with type 2 diabetes.
    Kunutsor SK; Balasubramanian VG; Zaccardi F; Gillies CL; Aroda VR; Seidu S; Khunti K
    Diabetes Obes Metab; 2024 Jun; 26(6):2069-2081. PubMed ID: 38409644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with meta-analysis.
    Giugliano D; Chiodini P; Maiorino MI; Bellastella G; Esposito K
    J Endocrinol Invest; 2019 Oct; 42(10):1165-1169. PubMed ID: 30955180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What matters in ADVANCE and ADVANCE-ON.
    Hamet P
    Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():20-9. PubMed ID: 22118707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucose control in diabetes: which target level to aim for?
    Laakso M; Cederberg H
    J Intern Med; 2012 Jul; 272(1):1-12. PubMed ID: 22321169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé.
    Bajaj M; Jialal I
    Metab Syndr Relat Disord; 2009 Apr; 7(2):79-81. PubMed ID: 19351292
    [No Abstract]   [Full Text] [Related]  

  • 12. Optimizing diabetes management through glucose profiling: a case-based approach.
    Streja DA
    Prim Care Diabetes; 2008 Dec; 2(4):167-73. PubMed ID: 18786873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of glycemic treatment choices on cardiovascular complications in type 2 diabetes.
    Weiss IA; Valiquette G; Schwarcz MD
    Cardiol Rev; 2009; 17(4):165-75. PubMed ID: 19525678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes. Insights from the extended follow-up of the ACCORD trial.
    Zoungas S; Woodward M
    Nat Rev Cardiol; 2011 Jun; 8(6):308-10. PubMed ID: 21502962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence.
    Rodríguez-Gutiérrez R; Montori VM
    Circ Cardiovasc Qual Outcomes; 2016 Sep; 9(5):504-12. PubMed ID: 27553599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study.
    Kawamori R; Node K; Hanafusa T; Atsumi Y; Naito Y; Oka Y
    Cardiovasc Diabetol; 2013 Sep; 12():131. PubMed ID: 24011395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of pharmacological treatments on micro- and macrovascular complications of type 2 diabetes: what is the level of evidence?
    Boussageon R; Gueyffier F; Cornu C
    Diabetes Metab; 2014 Jun; 40(3):169-75. PubMed ID: 24503191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is Hemoglobin A1c the Right Outcome for Studies of Diabetes?
    Lipska KJ; Krumholz HM
    JAMA; 2017 Mar; 317(10):1017-1018. PubMed ID: 28125758
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose-lowering interventions.
    Roussel R; Steg PG; Mohammedi K; Marre M; Potier L
    Diabetes Obes Metab; 2018 Feb; 20(2):238-244. PubMed ID: 28597588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is glycemic control a quinidine-like intervention?
    Bloomgarden ZT
    J Diabetes; 2014 Sep; 6(5):387-8. PubMed ID: 24842383
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.